Burning Rock Announces Results of 2025 Annual General Meeting
Rhea-AI Summary
Burning Rock (NASDAQ: BNR) announced that all shareholder resolutions at its 2025 annual general meeting held on Dec. 22, 2025 were duly passed.
Passed resolutions include: ratification of Ernst & Young Hua Ming LLP as auditor for the fiscal year ending Dec. 31, 2025 with directors authorized to set auditor remuneration; re-election of Feng Deng and Licen Lisa Xu as directors; and authorization for directors to take actions necessary to implement these resolutions.
Positive
- None.
Negative
- None.
News Market Reaction – BNR
In the Dec 23 session, BNR declined 6.93%, reflecting a notable negative market reaction. Argus tracked a trough of -8.7% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | AGM announcement | Neutral | -12.0% | Scheduled 2025 AGM with proposals on auditor and director elections. |
| Nov 20 | Q3 2025 earnings | Positive | -3.1% | Q3 revenue growth, margin improvement, and narrowed net loss. |
| Sep 24 | CDx approval Japan | Positive | -0.8% | MHLW approval of OncoScreen Plus CDx for capivasertib in breast cancer. |
| Sep 08 | Q2 2025 earnings | Positive | +9.2% | Q2 revenue growth, higher gross margin, sharply reduced net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often saw negative or muted reactions, including declines after a prior AGM announcement and positive clinical and earnings updates, with one strong gain on Q2 2025 results indicating inconsistent response to fundamentally positive developments.
Over the last few months, Burning Rock reported multiple financial and operational updates. Q2 and Q3 2025 results showed revenue growth, margin improvement, and narrowed net losses, while a Japan MHLW approval for the OncoGuide OncoScreen Plus CDx marked a key regulatory milestone. The announcement of the 2025 AGM on December 23, 2025 previously coincided with a notable share price decline. Today’s AGM results confirm those agenda items were approved, formalizing decisions previously outlined.
Key Terms
next generation sequencing medical
precision oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2025 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions:
- as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2025 be ratified and that the directors of the Company be authorized to determine the remuneration of the auditor;
- as an ordinary resolution, THAT Feng Deng and Licen Lisa Xu be re-elected as directors of the Company; and
- as an ordinary resolution, THAT each of the directors of the Company be authorized to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: ir.brbiotech.com.
Contact: IR@brbiotech.com
